Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH

Inclusion Criteria: * Patients hospitalized for a scheduled alcohol inpatient cessation * Aged 18-75 years old * Meeting DSM 5 criteria for severe AUD * Willing to participate * Signing a written informed consent * Patients with current social insurance * For childbearing age, sexually active females: efficacious contraceptive method during treatment and up to seven days after treatment administration Exclusion Criteria: * • Patients already scheduled for long term residential care after acute alcohol inpatient detoxification, not able to maintain the outpatient follow up * Patients not willing to attend post-discharge visits whatever the reason * Any unstable medical condition at entry, such as delirium, acute hepatic failure, hypokalaemia, liver cirrhosis whatever the stage, acute or chronic severe renal failure or any acute psychiatric condition * Liver enzymes (ALT and/or AST) above 3 times the upper limit of normal and/or bilirubin above 2 times the upper limit of normal * Current medication or need for medication with treatments metabolized by CYP 2C19 or CYP3A4 or UGT enzymes and having strong inhibitor/inducer properties (see list above), and/or current medication or need for medications containing valproate and derivates * Any medical history of epileptic seizure * Patients with current or past history of cardiac arrhythmias, myocardial infarction and stroke * Any history of suicidal attempt in the past 5 years or a score ≥1 to the Suicidal Ideation Attributes Scale (SIDAS) * To facilitate efficacy data interpretation, patients currently receiving or wanting to receive another approved pharmacological treatment aimed at alcohol abstinence maintenance (acamprosate, baclofene, disulfiram, nalmefene, naltrexone). * Other major current DSM 5 severe substance use disorder (like opiates, cocaine, amphetamines, ...) except for tobacco, cannabis smoking and benzodiazepines use disorders * Pregnancy and breast feeding * Known hypersensitivity to the active substance or to any of the excipients (including PEG) * Patients under guardianship * Patients in exclusion periods of other trials * Reversely, cannabis use or cannabis use disorders will not be an exclusion criteria